Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome

Yunxiong Wei(Tianjin First Center Hospital), Mingfeng Zhao(Nankai University), Wenyi Lu(Tianjin First Center Hospital), Xia Xiong(Chinese Academy of Sciences), Xin Jin(Nankai University), Ting Yuan(Goethe University Frankfurt), Xin Li(Tianjin Medical University General Hospital), Xiaoyuan He(Nankai University), Rui Sun(Nankai University), Tongtong Sun(Tianjin First Center Hospital), Hairong Lyu(Tianjin First Center Hospital)
Cancer Science
June 29, 2021
Cited by 71


Related Papers